HRMY at a glance
Harmony Biosciences Holdings, Inc. (HRMY, SEC CIK 1802665) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.5 million (up 21.5% from FY2024) and net income of $158.7 million. Diluted EPS was $2.71.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Harmony Biosciences Holdings, Inc. (HRMY) shares worth $1.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Budur Kumar on September 18, 2026 of 35,852 shares at $43.05 per share.
- In the last 90 days, HRMY insiders reported 0 open-market purchases ($0) and 7 open-market sales ($3.1M) on Form 4, a net sale of $3.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $868.5M
- +21.5% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$3.1M
- 13F holders
- 32 funds
- $1.0B · −1 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Neuroscience-focused biopharma developing innovative treatments for rare neurological diseases emphasizing sleep/wake disorders, rare epilepsy, and neurobehavioral conditions
- New products and expansions: Acquired orexin 2 receptor agonist BP1.15205 (preclinical), launched Phase 3 trials for next-gen pitolisant formulations (GR and HD), expanded rare epilepsy pipeline via Epygenix acquisition with EPX-100 and EPX-200
- Strategic shift: Diversified beyond pitolisant with Zynerba acquisition (ZYN002 cannabidiol gel), entry into orexin science, and cell replacement therapy collaboration with CiRC Biosciences
- Quantitative highlight: WAKIX net revenue $868.5M in 2025 with ~8,500 average patients on therapy; filed NDA for Pitolisant GR targeting Q1 2027 FDA review
- Noteworthy: FDA approvals expanded WAKIX pediatric indications for EDS (2024) and cataplexy (2026); Phase 3 negative RECONNECT trial led to phasing out ZYN002 in Fragile X syndrome
Risk Factors
- Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026
- Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks
- Operational risk: dependence on Bioprojet license for core pitolisant IP, with risk of termination restricting commercialization rights in the U.S.
- Competitive risk: WAKIX faces competition from modafinil, which showed non-inferiority, potentially limiting physician prescribing and market acceptance
- Financial risk: dependence on WAKIX sales for substantially all revenue, with failure to grow sales potentially causing loss of profitability and need for additional financing
Management Discussion & Analysis
- Revenue $868.5M, up 21.5% YoY (+$153.7M) driven by 18.3% volume growth and 7.0% price increase, offset by 3.6% higher rebates
- Gross margin 77.2% (cost of sales 22.8%) vs 78.1% (cost of sales 21.9%) in prior year, impacted by higher royalty tier
- R&D expenses $189.6M, up 30.0% (+$43.8M) led by EPX-100 (+$27.2M), ZYN002 (+$8.0M), and Pitolisant GR/HD (+$11.9M); offset by $7.7M decrease for Pitolisant IH
- Net income $158.7M, up from $145.5M; Operating income $208.5M vs $190.8M prior year
- Capital allocation: no specific buybacks or dividends disclosed; $0.5M rent/consulting fees; increased investments in clinical trials and manufacturing; forward-looking focus on advancing multiple Phase 3 programs and pursuing pediatric exclusivity with potential PDUFA dates in 2027-2028
AI summary of the HRMY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $261.3M, up 30.3% YoY from $200.5M, driven by units shipped up 26.5% and 7% pricing
- Gross margin 75.8% vs 81.0% YoY, with cost of product sold 24.2% vs 19.0%
- Operating income $89.3M vs $48.2M; operating margin 34.2% vs 24.0% YoY
- WAKIX strongest product, with average patients on therapy approximately 8,950 and formulary access above 80%
- Pitolisant GR NDA accepted; target PDUFA date April 1, 2027, while BP-205 Phase 1b preparation targets third quarter 2026
Risk Factors
- No risk-factors section provided; submitted text covers Items 2–6 and contains no stated changes from the 10-K
- Debt-default risk under TLA Credit Agreement incorporated by reference to Note 10
- Executive transition risk from Glenn Reicin separation agreement dated July 16, 2026
- Insider-trading compliance risk from Kumar Budur’s terminated and replaced Rule 10b5-1 arrangement
- Potential equity dilution from planned sales of up to 72,406 shares under Budur’s new arrangement
AI summary of the HRMY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q2 WAKIX revenue $261.3M, up 30% year over year; average patients rose 450 to 8,950
- 2026 WAKIX revenue guidance reiterated at $1.0B-$1.04B, supporting continued commercial momentum
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 4, 2026
Item 7.01: Regulation FD Disclosure
- Investor presentation posted August 4, 2026, providing management’s latest messaging for investors and analysts
- Exhibit 99.2 contains the substantive business, strategy and outlook disclosures
Item 2.02: Results of Operations and Financial Condition
- Investors should rely on the referenced earnings exhibit for fiscal-year 2026 performance details
- Disclaimers highlight material risks and no obligation to update projections outside legal requirements
Item EX-99.1: Item EX-99.1
- Preliminary Q2 2026 WAKIX revenue approximately $261M, up 30% year over year and 21% sequentially
- Full-year 2026 net revenue guidance reaffirmed at $1.0B-$1.04B, supporting continued commercial momentum
Item 7.01: Regulation FD Disclosure
- July 16, 2026 press release announced previously disclosed officer changes
- Exhibit 99.1 contains the substantive announcement and is incorporated by reference
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Glenn Reicin departing July 16, 2026 for other career opportunities
- Separation agreement provides employment-agreement severance benefits and pro-rated target bonus
Item 5.07: Submission of Matters to a Vote of Security Holders
- 50,381,309 shares represented at the May 14, 2026 annual meeting, establishing quorum
- All four Class III nominees elected through 2029, with Andreas Wicki receiving the highest withheld vote count at 21,372,779
AI summaries of HRMY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HRMY
Don't miss the next HRMY filing
- Alerts as it files. A push when HRMY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HRMY, by share count.
- Ask anything. An AI agent that reads every HRMY filing and answers with sources.
HRMY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Budur Kumar | M | Sep 18, 2026 | 25,446 | $30.27 |
| Budur Kumar | M | Sep 18, 2026 | 10,406 | - |
| Budur Kumar | M | Sep 18, 2026 | 10,406 | $30.69 |
| Budur Kumar | M | Sep 18, 2026 | 25,446 | - |
| Budur Kumar | Sell | Sep 18, 2026 | 35,852 | $43.05 |
| Budur Kumar | Sell | Sep 17, 2026 | 800 | $43.00 |
| Budur Kumar | M | Sep 17, 2026 | 400 | $30.69 |
| Budur Kumar | M | Sep 17, 2026 | 400 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $714.7M | $868.5M |
| Gross Profit | - | $557.9M | $670.1M |
| Operating Income | - | $190.8M | $208.5M |
| Net Income | - | $145.5M | $158.7M |
| Gross Margin | - | 78.1% | 77.2% |
| Op. Margin | - | 26.7% | 24.0% |
| Net Margin | - | 20.4% | 18.3% |
| Balance Sheet | |||
| Total Assets | $811.4M | $999.2M | $1.3B |
| Equity | - | $659.2M | $870.2M |
| ROE | - | 22.1% | 18.2% |
| Per Share | |||
| EPS | - | $2.51 | $2.71 |
| Cash Flow | |||
| Operating CF | - | $219.8M | $348.2M |
| CapEx | $312K | $1.2M | $310K |
Source: XBRL data in Harmony Biosciences Holdings, Inc. (HRMY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HRMY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $1.01B |
| Q1 2026 | 33 | $805.3M |
| Q4 2025 | 30 | $954.3M |
| Q3 2025 | 31 | $708.9M |
| Q2 2025 | 31 | $801.7M |
| Q1 2025 | 28 | $633.1M |
| Q4 2024 | 24 | $597.4M |
| Q3 2024 | 21 | $192.5M |
- FMR LLC (Fidelity)+416.5K (+13%)
- Dimensional Fund Advisors+317.1K (+15%)
- Two Sigma Investments+225.7K (+31%)
- AQR Capital Management+218.1K (+30%)
- Vanguard Portfolio Management LLC+166.1K (+6%)
- Goldman Sachs Group−835.7K (-67%)
- Millennium Management−634.5K (-66%)
- Citadel Advisors LLC−329.8K (-56%)
- JPMorgan Chase & Co−309.4K (-38%)
- Morgan Stanley−297.3K (-29%)
- Raymond James Financial−41.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 230 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HRMY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 14, 2026 | - | Analysis | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 4 | Apr 6, 2026 | - | - | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
| 10-K | Feb 24, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 24, 2026 | - | Analysis | - |
| 4 | Jan 28, 2026 | - | - | |
| 4 | Jan 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HRMY SEC filings: frequently asked questions
Are HRMY insiders buying or selling?
In the last 90 days, Harmony Biosciences Holdings, Inc. (HRMY) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $3.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HRMY stock?
As of June 30, 2026, the largest Harmony Biosciences Holdings, Inc. (HRMY) holders among the 13F filers tracked by SignalX were BlackRock ($258.6 million), FMR LLC (Fidelity) ($130.1 million), Vanguard Portfolio Management LLC ($104.9 million), Dimensional Fund Advisors ($87.1 million), Vanguard Capital Management LLC ($76.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HRMY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.5 million (up 21.5% from FY2024) and net income of $158.7 million. Diluted EPS was $2.71. The figures come from the XBRL data in the 10-K.
What are the main risks in HRMY's latest 10-K?
In the 10-K filed February 24, 2026, Harmony Biosciences Holdings, Inc. (HRMY) flagged: Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026. Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks. (AI summary of the Risk Factors section.)
What did HRMY report in its latest 8-K?
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q2 WAKIX revenue $261.3M, up 30% year over year; average patients rose 450 to 8,950.
What are the latest HRMY SEC filings?
Harmony Biosciences Holdings, Inc. (HRMY) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 18, 2026.
What is HRMY's SEC CIK number?
Harmony Biosciences Holdings, Inc. (HRMY)'s SEC Central Index Key (CIK) is 1802665. EDGAR lists every HRMY filing under that number.
Ask anything about HRMY
The research agent reads HRMY's filings, financials, insider trades and 13F holders, then answers with sources.